Taxotere has been approved in 23 countries and is now available in 10. More than half of the women who have failed other therapies respond, meaning they see tumor shrinkage and an improvement in symptoms.
Breast cancer is a condition marked by the growth of abnormal cells in glandular breast tissue.
About 26,000 women are diagnosed with and nearly 10,500 die from breast cancer each year in France. For those women in particular there is now new hope with Taxotere since it is the most active agent available today for the treatment of breast cancer. The new agent has been studied extensively in clinical trials in France and the rest of the world. RPR is committed to continue its research to develop innovative new therapies to meet the unmet medical needs of cancer patients. Taxotere acts on the internal skeleton by promoting the assembly and blocking the disassembly of microtubules, which prohibits cancer cell division and stops tumor growth.